# Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

> **NCT06144944** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 160 (estimated)

## Conditions studied

- Breast Cancer Invasive
- Hormone-receptor-positive Breast Cancer
- HER2 Low Breast Carcinoma
- Early-stage Breast Cancer

## Interventions

- **DRUG:** Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
- **DRUG:** Epirubicin or doxorubicin, cyclophosphamide, paclitaxel

## Key facts

- **NCT ID:** NCT06144944
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-17
- **Primary completion:** 2026-06-30
- **Final completion:** 2031-12-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06144944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06144944, "Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06144944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*